aTyr Pharma, Inc.(US:ATYR) Prnewswireยท2025-10-20 12:45Core Points - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [2][4] - The company's EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price from $6.03 to $1.02, a decline of 83.2% in one day [2][3] - Shareholders who purchased shares during the class period from January 16, 2025, to September 12, 2025, are encouraged to register for the class action, with a lead plaintiff deadline set for December 8, 2025 [3][4] Company Information - The Gross Law Firm is representing shareholders in the class action, emphasizing its commitment to protecting investors from deceit and fraud [4][5] - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4]